APSR2026-974

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP11-025
P67
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1243270-46904-#APSR2026-974_433769.pdf
Format: PDF Only
09. Asthma
1

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

MUHAMMED ANAS AYOOB * ZAYED MILITARY HOSPITAL PULMONARY MEDICINE ABU DHABI United Arab Emirates
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
MUHAMMED ANAS
AYOOB
dranazm@gmail.com
+971547891323
41-50
United Arab Emirates
Original Research
Real-World Effectiveness and Clinical Outcomes of Biologic Therapy in Severe Asthma: A Single-Centre Experience from the United Arab Emirates
Maximum 25 words
Abstract Content
Biologic therapies have revolutionized the management of severe asthma by targeting specific inflammatory pathways and reducing disease burden. Despite these advances, real-world evidence from the Middle East is limited. This study assessed the effectiveness of biologic therapies in patients with severe asthma treated at a tertiary care center in the United Arab Emirates (UAE).
This retrospective observational cohort study included 114 adults with severe asthma who received biologic therapy (dupilumab, mepolizumab, benralizumab, omalizumab, or tezepelumab) between January 2020 and December 2025. Clinical outcomes were evaluated at baseline and after 12 months of treatment. The primary outcome was the change in annual exacerbation frequency. Secondary outcomes included Asthma Control Test (ACT) score, lung function, blood eosinophil count, fractional exhaled nitric oxide (FeNO), hospitalization frequency, and systemic corticosteroid use.
The mean exacerbation frequency decreased from 2.40 to 1.15 episodes per year, representing a 52% reduction (p<0.001). ACT scores improved significantly from 11.9±2.1 to 18.1±4.5 (p<0.001), with 78.1% of patients achieving a clinically meaningful improvement. Mean FEV₁ increased from 2.63 to 2.76 liters (p=0.001). Blood eosinophil counts decreased by 54%, and FeNO levels decreased by 36.8% (both p<0.001). Hospitalization rates declined by 47%, and systemic corticosteroid courses decreased by 48% (both p<0.001). Among the biologics, dupilumab was associated with the greatest reduction in exacerbation rates and the highest ACT responder rate, although between-group differences were not statistically significant.
Biologic therapy was associated with significant improvements in asthma control, exacerbation frequency, lung function, inflammatory biomarkers, and healthcare utilization in this real-world UAE cohort. These findings support the effectiveness of biologics in routine clinical practice and contribute important regional evidence for the management of severe asthma.
 
 
 
 
 
Yes
Yes
https://storage.unitedwebnetwork.com/files/1285/1243270-37089-exacerbatn_399335.png
JPG or JPEG or PNG format ONLY
Severe asthma, Biologic therapy, Real-world evidence
maximum 3 keywords and no abbreviations, separated by commas
Nil
293